Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes

Cell Reports

Volumn 20, Issue 1, 2017, Pages 76-88

  Haas, Laura T ^a,b   Salazar, Santiago V ^a   Smith, Levi M ^a   Zhao, Helen R ^a   Cox, Timothy O ^a   Herber, Charlotte S ^a   Degnan, Andrew P ^c   Balakrishnan, Anand ^c   Macor, John E ^c   Albright, Charles F ^c   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Alzheimer; amyloid ; metabotropic glutamate receptor 5; mGluR5; oligomer; prion protein; silent allosteric modulator; transgenic mouse

Indexed keywords

AMYLOID BETA PROTEIN; BMS 984923; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; OLIGOMER; PRION PROTEIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; NEUROPROTECTIVE AGENT; PRESENILIN; PROTEIN BINDING;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SYNAPSE; THERAPEUTIC INDEX; TRANSGENIC MOUSE; ALLOSTERISM; ANIMAL; BRAIN; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; MEMORY; METABOLISM; PRION; SYNAPTIC TRANSMISSION;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; HEK293 CELLS; HUMANS; MEMORY; MICE; NEUROPROTECTIVE AGENTS; PHENOTYPE; PRESENILINS; PRIONS; PROTEIN BINDING; RECEPTOR, METABOTROPIC GLUTAMATE 5; SYNAPTIC TRANSMISSION;

EID: 85021834010     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.06.023     Document Type: Article

References (63)

1. Abou Farha, K., Bruggeman, R., Baljé-Volkers, C., Metabotropic glutamate receptor 5 negative modulation in phase I clinical trial: potential impact of circadian rhythm on the neuropsychiatric adverse reactions-do hallucinations matter?. ISRN Psychiatry, 2014, 2014, 652750.
2. Ballatore, C., Lee, V.M., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8 (2007), 663–672.
3. Beraldo, F.H., Ostapchenko, V.G., Caetano, F.A., Guimaraes, A.L., Ferretti, G.D., Daude, N., Bertram, L., Nogueira, K.O., Silva, J.L., Westaway, D., et al. Regulation of amyloid β oligomer binding to neurons and neurotoxicity by the prion protein-mGluR5 complex. J. Biol. Chem. 291 (2016), 21945–21955.
4. Berman, D.E., Dall'Armi, C., Voronov, S.V., McIntire, L.B., Zhang, H., Moore, A.Z., Staniszewski, A., Arancio, O., Kim, T.W., Di Paolo, G., Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nat. Neurosci. 11 (2008), 547–554.
5. Bhakar, A.L., Dölen, G., Bear, M.F., The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35 (2012), 417–443.
6. Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, D., Flor, P.J., Nicoletti, F., Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab. 21 (2001), 1013–1033.
7. Campbell, U.C., Lalwani, K., Hernandez, L., Kinney, G.G., Conn, P.J., Bristow, L.J., The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl.) 175 (2004), 310–318.
8. Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., Ashe, K.H., Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005), 79–84.
9. Foster, D.J., Conn, P.J., Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron 94 (2017), 431–446.
10. Gasparini, F., Spooren, W., Allosteric modulators for mGlu receptors. Curr Neuropharmacol. 5 (2007), 187–194.
11. Gimbel, D.A., Nygaard, H.B., Coffey, E.E., Gunther, E.C., Laurén, J., Gimbel, Z.A., Strittmatter, S.M., Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30 (2010), 6367–6374.
12. Gregory, K.J., Malosh, C., Turlington, M., Morrison, R., Vinson, P., Daniels, J.S., Jones, C., Niswender, C.M., Conn, P.J., Lindsley, C.W., and Stauffer, S.R. (2010). Identification of a high affinity MPEP-site silent allosteric modulator (SAM) for the metabotropic glutamate subtype 5 receptor (mGlu5). Probe Reports from the NIH Molecular Libraries Program, http://www.ncbi.nlm.nih.gov/books/NBK280039/.
13. Gregory, K.J., Dong, E.N., Meiler, J., Conn, P.J., Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60 (2011), 66–81.
14. Gregory, K.J., Noetzel, M.J., Rook, J.M., Vinson, P.N., Stauffer, S.R., Rodriguez, A.L., Emmitte, K.A., Zhou, Y., Chun, A.C., Felts, A.S., et al. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol. Pharmacol. 82 (2012), 860–875.
15. Haas, L.T., Strittmatter, S.M., Oligomers of Amyloid β prevent physiological activation of the cellular prion protein-metabotropic glutamate receptor 5 complex by glutamate in Alzheimer disease. J. Biol. Chem. 291 (2016), 17112–17121.
16. Haas, L.T., Kostylev, M.A., Strittmatter, S.M., Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J. Biol. Chem. 289 (2014), 28460–28477.
17. Haas, L.T., Salazar, S.V., Kostylev, M.A., Um, J.W., Kaufman, A.C., Strittmatter, S.M., Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. Brain 139 (2016), 526–546.
18. Hamilton, A., Esseltine, J.L., DeVries, R.A., Cregan, S.P., Ferguson, S.S., Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol. Brain, 7, 2014, 40.
19. Hamilton, A., Vasefi, M., Vander Tuin, C., McQuaid, R.J., Anisman, H., Ferguson, S.S., Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model. Cell Rep. 15 (2016), 1859–1865.
20. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
21. Heidinger, V., Manzerra, P., Wang, X.Q., Strasser, U., Yu, S.P., Choi, D.W., Behrens, M.M., Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J. Neurosci. 22 (2002), 5452–5461.
22. Heiss, J.K., Barrett, J., Yu, Z., Haas, L.T., Kostylev, M.A., Strittmatter, S.M., Early activation of experience-independent dendritic spine turnover in a mouse model of Alzheimer's disease. Cereb. Cortex., 2016, 10.1093/cercor/bhw188 Published online June 29, 2016.
23. Hong, S., Beja-Glasser, V.F., Nfonoyim, B.M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K.M., Shi, Q., Rosenthal, A., Barres, B.A., et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352 (2016), 712–716.
24. Hu, N.W., Nicoll, A.J., Zhang, D., Mably, A.J., O'Malley, T., Purro, S.A., Terry, C., Collinge, J., Walsh, D.M., Rowan, M.J., mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat. Commun., 5, 2014, 3374.
25. Huang, H., Degnan, A.P., Balakrishnan, A., Easton, A., Gulianello, M., Huang, Y., Matchett, M., Mattson, G., Miller, R., Santone, K.S., et al. Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box. Bioorg. Med. Chem. Lett. 26 (2016), 4165–4169.
26. Jankowsky, J.L., Xu, G., Fromholt, D., Gonzales, V., Borchelt, D.R., Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62 (2003), 1220–1227.
27. Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N.A., Copeland, N.G., Lee, M.K., Younkin, L.H., Wagner, S.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13 (2004), 159–170.
28. Kaufman, A.C., Salazar, S.V., Haas, L.T., Yang, J., Kostylev, M.A., Jeng, A.T., Robinson, S.A., Gunther, E.C., van Dyck, C.H., Nygaard, H.B., Strittmatter, S.M., Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol. 77 (2015), 953–971.
29. Kostylev, M.A., Kaufman, A.C., Nygaard, H.B., Patel, P., Haas, L.T., Gunther, E.C., Vortmeyer, A., Strittmatter, S.M., Prion-protein-interacting amyloid-β oligomers of high molecular weight are tightly correlated with memory impairment in multiple alzheimer mouse models. J. Biol. Chem. 290 (2015), 17415–17438.
30. Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L., Klein, W.L., Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27 (2007), 796–807.
31. Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95 (1998), 6448–6453.
32. Larson, M., Sherman, M.A., Amar, F., Nuvolone, M., Schneider, J.A., Bennett, D.A., Aguzzi, A., Lesné, S.E., The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J. Neurosci. 32 (2012), 16857–16871a.
33. Laurén, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W., Strittmatter, S.M., Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (2009), 1128–1132.
34. Lesné, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006), 352–357.
35. Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., Selkoe, D., Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62 (2009), 788–801.
36. Lu, Y.M., Jia, Z., Janus, C., Henderson, J.T., Gerlai, R., Wojtowicz, J.M., Roder, J.C., Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17 (1997), 5196–5205.
37. Lüscher, C., Huber, K.M., Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65 (2010), 445–459.
38. Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F., Lindemann, L., Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74 (2012), 49–56.
39. Molck, C., Harpsoe, K., Gloriam, D.E., Mathiesen, J.M., Nielsen, S.M., Bräuner-Osborne, H., mGluR5: exploration of orthosteric and allosteric ligand binding pockets and their applications to drug discovery. Neurochem Res. 39 (2014), 1862–1875.
40. Nicodemo, A.A., Pampillo, M., Ferreira, L.T., Dale, L.B., Cregan, T., Ribeiro, F.M., Ferguson, S.S., Pyk2 uncouples metabotropic glutamate receptor G protein signaling but facilitates ERK1/2 activation. Mol. Brain, 3, 2010, 4.
41. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., LaFerla, F.M., Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003), 409–421.
42. Overk, C.R., Cartier, A., Shaked, G., Rockenstein, E., Ubhi, K., Spencer, B., Price, D.L., Patrick, C., Desplats, P., Masliah, E., Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5–implications for dementia with Lewy bodies. Mol. Neurodegener., 9, 2014, 18.
43. Palop, J.J., Mucke, L., Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13 (2010), 812–818.
44. Park, J.H., Widi, G.A., Gimbel, D.A., Harel, N.Y., Lee, D.H., Strittmatter, S.M., Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. J. Neurosci. 26 (2006), 13279–13286.
45. Parmentier-Batteur, S., Hutson, P.H., Menzel, K., Uslaner, J.M., Mattson, B.A., O'Brien, J.A., Magliaro, B.C., Forest, T., Stump, C.A., Tynebor, R.M., et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators–development challenges for a promising novel antipsychotic target. Neuropharmacology 82 (2014), 161–173.
46. Porter, R.H., Jaeschke, G., Spooren, W., Ballard, T.M., Büttelmann, B., Kolczewski, S., Peters, J.U., Prinssen, E., Wichmann, J., Vieira, E., et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315 (2005), 711–721.
47. Raka, F., Di Sebastiano, A.R., Kulhawy, S.C., Ribeiro, F.M., Godin, C.M., Caetano, F.A., Angers, S., Ferguson, S.S., Ca(2+)/calmodulin-dependent protein kinase II interacts with group I metabotropic glutamate and facilitates receptor endocytosis and ERK1/2 signaling: role of β-amyloid. Mol. Brain, 8, 2015, 21.
48. Renner, M., Lacor, P.N., Velasco, P.T., Xu, J., Contractor, A., Klein, W.L., Triller, A., Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66 (2010), 739–754.
49. Ribeiro, F.M., Paquet, M., Cregan, S.P., Ferguson, S.S., Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets. 9 (2010), 574–595.
50. Rodriguez, A.L., Grier, M.D., Jones, C.K., Herman, E.J., Kane, A.S., Smith, R.L., Williams, R., Zhou, Y., Marlo, J.E., Days, E.L., et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 78 (2010), 1105–1123.
51. Rook, J.M., Xiang, Z., Lv, X., Ghoshal, A., Dickerson, J.W., Bridges, T.M., Johnson, K.A., Foster, D.J., Gregory, K.J., Vinson, P.N., et al. Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents. Neuron 86 (2015), 1029–1040.
52. Rutrick, D., Stein, D.J., Subramanian, G., Smith, B., Fava, M., Hasler, G., Cha, J.H., Gasparini, F., Donchev, T., Ocwieja, M., et al. Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther. 34 (2017), 524–541.
53. Scheff, S.W., DeKosky, S.T., Price, D.A., Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol. Aging 11 (1990), 29–37.
54. Selkoe, D.J., Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8 (2016), 595–608.
55. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008), 837–842.
56. Sheffler, D.J., Gregory, K.J., Rook, J.M., Conn, P.J., Allosteric modulation of metabotropic glutamate receptors. Adv Pharmacol. 62 (2011), 37–77.
57. Um, J.W., Nygaard, H.B., Heiss, J.K., Kostylev, M.A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E.C., Strittmatter, S.M., Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15 (2012), 1227–1235.
58. Um, J.W., Kaufman, A.C., Kostylev, M., Heiss, J.K., Stagi, M., Takahashi, H., Kerrisk, M.E., Vortmeyer, A., Wisniewski, T., Koleske, A.J., et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron 79 (2013), 887–902.
59. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002), 535–539.
60. Wang, Q., Walsh, D.M., Rowan, M.J., Selkoe, D.J., Anwyl, R., Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24 (2004), 3370–3378.
61. Xu, J., Zhu, Y., Contractor, A., Heinemann, S.F., mGluR5 has a critical role in inhibitory learning. J. Neurosci. 29 (2009), 3676–3684.
62. Yang, F., Snyder, L.B., Balakrishnan, A., Brown, J.M., Sivarao, D.V., Easton, A., Fernandes, A., Gulianello, M., Hanumegowda, U.M., Huang, H., et al. Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5. ACS Med. Chem. Lett. 7 (2016), 289–293.
63. Zhang, H., Wu, L., Pchitskaya, E., Zakharova, O., Saito, T., Saido, T., Bezprozvanny, I., neuronal store-operated calcium entry and mushroom spine loss in amyloid precursor protein knock-in mouse model of Alzheimer's disease. J. Neurosci. 35 (2015), 13275–13286.